U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C26H27N3O5S
Molecular Weight 493.5768
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DASABUVIR

SMILES

CC(C)(C)c1cc(cc(-c2ccc3cc(ccc3c2)NS(=O)(=O)C)c1OC)-n4ccc(nc4=O)O

InChI

InChIKey=NBRBXGKOEOGLOI-UHFFFAOYSA-N
InChI=1S/C26H27N3O5S/c1-26(2,3)22-15-20(29-11-10-23(30)27-25(29)31)14-21(24(22)34-4)18-7-6-17-13-19(28-35(5,32)33)9-8-16(17)12-18/h6-15,28H,1-5H3,(H,27,30,31)

HIDE SMILES / InChI

Molecular Formula C26H27N3O5S
Molecular Weight 493.5768
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/26567871

Dasabuvir is a non-nucleoside inhibitor of the hepatitis C virus (HCV) NS5B palm polymerase inhibitor. It is used in the treatment of adult patients with chronic hepatitis C virus infection in combination with ombitasvir, paritaprevir, and ritonavir as the combination product Viekira Pak. Viekira PAK combines three direct-acting antiviral agents with distinct mechanisms of action and non-overlapping resistance profiles to target HCV at multiple steps in the viral lifecycle. Dasabuvir is extensively evaluated in large clinical trials and shown excellent sustained virological response among hepatitis C virus genotype1 patient population in combination with other oral direct acting antivirals, with good safety profile and tolerance.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
2.8 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
VIEKIRA PAK (COPACKAGED)

Approved Use

Treatment of adult patients with chronic hepatitis C virus (HCV): genotype 1b without cirrhosis or with compensated cirrhosis, genotype 1a without cirrhosis or with compensated cirrhosis for use in combination with ribavirin.

Launch Date

1.4189472E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2110 ng/mL
1000 mg 2 times / day multiple, oral
dose: 1000 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DASABUVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
320 ng/mL
200 mg 2 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DASABUVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
912 ng/mL
400 mg 2 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DASABUVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1130 ng/mL
600 mg 2 times / day multiple, oral
dose: 600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DASABUVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
15800 ng × h/mL
1000 mg 2 times / day multiple, oral
dose: 1000 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DASABUVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2620 ng × h/mL
200 mg 2 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DASABUVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
7050 ng × h/mL
400 mg 2 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DASABUVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
8800 ng × h/mL
600 mg 2 times / day multiple, oral
dose: 600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DASABUVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6.52 h
1000 mg 2 times / day multiple, oral
dose: 1000 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DASABUVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
6.87 h
400 mg 2 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DASABUVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
6.87 h
600 mg 2 times / day multiple, oral
dose: 600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DASABUVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
0.1%
1000 mg 2 times / day multiple, oral
dose: 1000 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DASABUVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.1%
200 mg 2 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DASABUVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.1%
400 mg 2 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DASABUVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.1%
600 mg 2 times / day multiple, oral
dose: 600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DASABUVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1600 mg 2 times / day multiple, oral
Highest studied dose
Dose: 1600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 2 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sources:
2000 mg single, oral
Highest studied dose
Dose: 2000 mg
Route: oral
Route: single
Dose: 2000 mg
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sources:
600 mg 2 times / day multiple, oral
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: hepatitis C virus
Age Group: adult
Sources:
PubMed

PubMed

TitleDatePubMed
New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir.
2016
Dasabuvir (ABT333) for the treatment of chronic HCV genotype I: a new face of cure, an expert review.
2016
Patents

Sample Use Guides

250 mg tablet twice daily (morning and evening) with a meal without regard to fat or calorie content.
Route of Administration: Oral
The EC50 values of dasabuvir against genotype 1a-H77 and 1b-Con1 strains in HCV replicon cell culture assays were 7.7 nM and 1.8 nM, respectively. The median EC50 values of dasabuvir against HCV replicons containing NS5B genes from a panel of genotype 1a and 1b isolates from treatment-naïve subjects were 0.6 nM (range 0.4 nM to 2.1 nM; n = 11) and 0.3 nM (range 0.2 nM to 2 nM; n = 10), respectively.
Substance Class Chemical
Created
by admin
on Sat Jun 26 07:37:54 UTC 2021
Edited
by admin
on Sat Jun 26 07:37:54 UTC 2021
Record UNII
DE54EQW8T1
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DASABUVIR
DASH   INN   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
DASABUVIR [INN]
Common Name English
N-(6-(3-TERT-BUTYL-5-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)-2-METHOXYPHENYL)NAPHTHALEN-2-YL)METHANESULFONAMIDE
Systematic Name English
DASABUVIR [MI]
Common Name English
METHANESULFONAMIDE, N-(6-(5-(3,4-DIHYDRO-2,4-DIOXO-1(2H)-PYRIMIDINYL)-3-(1,1-DIMETHYLETHYL)-2-METHOXYPHENYL)-2-NAPHTHALENYL)-
Systematic Name English
DASABUVIR [USAN]
Common Name English
ABT-333
Code English
DASABUVIR [WHO-DD]
Common Name English
DASABUVIR [VANDF]
Common Name English
Classification Tree Code System Code
WHO-ATC J05AX66
Created by admin on Sat Jun 26 07:37:55 UTC 2021 , Edited by admin on Sat Jun 26 07:37:55 UTC 2021
WHO-ATC J05AP09
Created by admin on Sat Jun 26 07:37:55 UTC 2021 , Edited by admin on Sat Jun 26 07:37:55 UTC 2021
WHO-ATC J05AP52
Created by admin on Sat Jun 26 07:37:55 UTC 2021 , Edited by admin on Sat Jun 26 07:37:55 UTC 2021
FDA ORPHAN DRUG 484715
Created by admin on Sat Jun 26 07:37:55 UTC 2021 , Edited by admin on Sat Jun 26 07:37:55 UTC 2021
NCI_THESAURUS C281
Created by admin on Sat Jun 26 07:37:55 UTC 2021 , Edited by admin on Sat Jun 26 07:37:55 UTC 2021
NDF-RT N0000191257
Created by admin on Sat Jun 26 07:37:55 UTC 2021 , Edited by admin on Sat Jun 26 07:37:55 UTC 2021
WHO-ATC J05AX16
Created by admin on Sat Jun 26 07:37:55 UTC 2021 , Edited by admin on Sat Jun 26 07:37:55 UTC 2021
Code System Code Type Description
LACTMED
Dasabuvir
Created by admin on Sat Jun 26 07:37:55 UTC 2021 , Edited by admin on Sat Jun 26 07:37:55 UTC 2021
PRIMARY
CAS
1132935-63-7
Created by admin on Sat Jun 26 07:37:55 UTC 2021 , Edited by admin on Sat Jun 26 07:37:55 UTC 2021
PRIMARY
EVMPD
SUB131059
Created by admin on Sat Jun 26 07:37:55 UTC 2021 , Edited by admin on Sat Jun 26 07:37:55 UTC 2021
PRIMARY
FDA UNII
DE54EQW8T1
Created by admin on Sat Jun 26 07:37:55 UTC 2021 , Edited by admin on Sat Jun 26 07:37:55 UTC 2021
PRIMARY
PUBCHEM
56640146
Created by admin on Sat Jun 26 07:37:55 UTC 2021 , Edited by admin on Sat Jun 26 07:37:55 UTC 2021
PRIMARY
RXCUI
1597381
Created by admin on Sat Jun 26 07:37:55 UTC 2021 , Edited by admin on Sat Jun 26 07:37:55 UTC 2021
PRIMARY RxNorm
DRUG BANK
DB09183
Created by admin on Sat Jun 26 07:37:55 UTC 2021 , Edited by admin on Sat Jun 26 07:37:55 UTC 2021
PRIMARY
MERCK INDEX
M11828
Created by admin on Sat Jun 26 07:37:55 UTC 2021 , Edited by admin on Sat Jun 26 07:37:55 UTC 2021
PRIMARY
ChEMBL
CHEMBL3137312
Created by admin on Sat Jun 26 07:37:55 UTC 2021 , Edited by admin on Sat Jun 26 07:37:55 UTC 2021
PRIMARY
CAS
1221573-79-0
Created by admin on Sat Jun 26 07:37:55 UTC 2021 , Edited by admin on Sat Jun 26 07:37:55 UTC 2021
NO STRUCTURE GIVEN
NDF-RT
N0000191272
Created by admin on Sat Jun 26 07:37:55 UTC 2021 , Edited by admin on Sat Jun 26 07:37:55 UTC 2021
PRIMARY UGT1A1 Inhibitors [MoA]
INN
9741
Created by admin on Sat Jun 26 07:37:55 UTC 2021 , Edited by admin on Sat Jun 26 07:37:55 UTC 2021
PRIMARY
NDF-RT
N0000190113
Created by admin on Sat Jun 26 07:37:55 UTC 2021 , Edited by admin on Sat Jun 26 07:37:55 UTC 2021
PRIMARY Breast Cancer Resistance Protein Inhibitors [MoA]
DRUG CENTRAL
4914
Created by admin on Sat Jun 26 07:37:55 UTC 2021 , Edited by admin on Sat Jun 26 07:37:55 UTC 2021
PRIMARY
NDF-RT
N0000191258
Created by admin on Sat Jun 26 07:37:55 UTC 2021 , Edited by admin on Sat Jun 26 07:37:55 UTC 2021
PRIMARY RNA Replicase Inhibitors [MoA]
NCI_THESAURUS
C123880
Created by admin on Sat Jun 26 07:37:55 UTC 2021 , Edited by admin on Sat Jun 26 07:37:55 UTC 2021
PRIMARY
Related Record Type Details
EXCRETED UNCHANGED
URINE
TRANSPORTER -> SUBSTRATE
EXCRETED UNCHANGED
FECAL
BINDER->LIGAND
BINDING
METABOLIC ENZYME -> SUBSTRATE
MAJOR
Related Record Type Details
METABOLITE -> PARENT
PLASMA; URINE
METABOLITE -> PARENT
PLASMA
METABOLITE -> PARENT
FECAL
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC
blood-to-plasma ratio PHARMACOKINETIC